All In Biotech

Drug Trial Radar · NCT01928394

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,163 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,163

Actual

Start

Oct 24, 2013

Primary completion

Feb 5, 2019

Study completion Nov 18, 2024

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • NivolumabBiological

  • IpilimumabBiological

  • CobimetinibDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate ( ORR )Time frame: 60 months

Locations

38 sites in 8 countries. Site status is shown where the registry gives one.

  • Local Institution - 0047

    Muscle Shoals, Alabama

  • Local Institution - 0044

    Aurora, Colorado

  • Local Institution - 0015

    New Haven, Connecticut

  • Local Institution - 0046

    Gainesville, Florida

  • Local Institution - 0021

    Tampa, Florida

  • Local Institution - 0001

    Atlanta, Georgia

  • Local Institution - 0004

    Baltimore, Maryland

  • Local Institution - 0005

    Boston, Massachusetts

  • Local Institution - 0043

    Boston, Massachusetts

  • Local Institution - 0049

    Omaha, Nebraska

  • Local Institution - 0045

    Mineola, New York

  • Local Institution - 0006

    New York, New York

  • Local Institution - 0003

    Charlotte, North Carolina

  • Local Institution - 0008

    Durham, North Carolina

  • Local Institution - 0007

    Portland, Oregon

  • Local Institution - 0011

    Franklin, Tennessee

  • Local Institution - 0002

    Nashville, Tennessee

  • Local Institution - 0009

    Houston, Texas

  • Local Institution - 0042

    Seattle, Washington

  • Local Institution - 0038

    Toronto, Ontario, Canada

  • Local Institution - 0039

    Copenhagen, Denmark

  • Local Institution - 0036

    Tampere, Finland

  • Local Institution - 0014

    Helsinki, Uusimaa, Finland

  • Local Institution - 0048

    Bonn, Germany

  • Local Institution - 0026

    Frankfurt, Germany

  • Local Institution - 0016

    Heidelberg, Germany

  • Local Institution - 0050

    Kassel, Germany

  • Local Institution - 0024

    Bologna, Italy

  • Local Institution - 0019

    Milan, Italy

  • Local Institution - 0020

    Naples, Italy

  • Local Institution - 0032

    Padova, Italy

  • Local Institution - 0037

    Barcelona, Spain

  • Local Institution - 0023

    Madrid, Spain

  • Local Institution - 0017

    Madrid, Spain

  • Local Institution - 0010

    Madrid, Spain

  • Local Institution - 0018

    London, Greater London, United Kingdom

  • Local Institution - 0012

    Glasgow, Lanarkshire, United Kingdom

  • Local Institution - 0013

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.